Senores Pharmaceuticals IPO Details, GMP Price, Date, Review

Senores Pharmaceuticals IPO details Today : Senores Pharmaceuticals IPO details Today is Open on [.] 2024 and Close on [.] 2024. Senores Pharmaceuticals IPO to Raise [.] shares (Approx ₹[.] Cr) via IPO. The Fresh issue of  [.] shares (Approx ₹[.] Cr) and The Offer For Sale is 2,700,000 shares (Approx ₹[.] Cr).

We are a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Our strength lies in identifying, developing and manufacturing a diverse range of specialty,
underpenetrated and complex pharmaceutical products establishing us as a preferred partner to certain customers.

Through data analytics, research, market assessment and experienced management, we strategically identify commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets. We leverage our R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products

Our business is primarily focussed on the Regulated Markets of US and Canada. We have a presence in the Emerging Markets across 43 countries. We also manufacture critical care injectables and APIs.

Object of the Issue

1. Funding the capital expenditure requirements by investment in of one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility.
2. Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company and our Subsidiaries, namely, Havix, Ratnatris Pharmaceutical Private Limited (“Ratnatris”) and Senores Pharmaceuticals Inc. (“SPI”).
3. Funding the working capital requirements of our Company and our Subsidiaries, namely, SPI and Ratnatris.
4. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

Our Company Promoters

1. Swapnil Jatinbhai Shah
2. Ashokkumar Vijaysinh Barot

Qualitative Factors

• Ability to cater to the Regulated Markets through our US FDA approved formulation manufacturing facility in the US.
• Distinct niche product portfolio built in a short span for Regulated Markets.
• Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets.
• Presence in the Emerging Markets with a strong product portfolio, including specialty or complex products.
• Strong R&D capabilities driving our differentiated portfolio of products.
• Professional and dedicated management teams for our diverse business verticals.

Comparison of Accounting Ratios with Listed Peer Group Companies

• Senores Pharmaceuticals Limited
• Ajanta Pharma Limited
• Alembic Pharmaceuticals Limited
• Caplin Point Laboratories Limited
• Gland Pharma Limited
• Strides Pharma Science Limited

Also Read: Picturepost Studios IPO 

Senores Pharmaceuticals Company Contact Details

1101 to 1103, 11th floor,
South Tower,
ONE 42 Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad, Gujarat-380054
Tel: +91-79-29999857
Email: cs@senorespharma.com
Website: www.senorespharma.com
Contact Person: Nidhi Dilipbhai Kapadia

Senores Pharmaceuticals IPO Registrar

Link Intime India Private Limited
C 101, 1st Floor, 247 Park
Lal Bahadur Shastri Marg, Vikhroli (West)
Maharashtra, India 400083
Tel: +91 81081 14949
E-mail: senorespharma.ipo@linkintime.co.in
Website: www.linkintime.co.in
Investor grievance e-mail: senorespharma.ipo@linkintime.co.in
Contact person: Shanti Gopalkrishnan